Oric Pharmaceuticals Announces $125M Private Placement Financing -january 22, 2024 At 08:31 Am Est | Marketscreener
(marketscreener.com) Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New Enterprise Associates , and Nextech Pro forma cash and investments expected to fund current operating plan into late 2026 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 22, 2024 -- ORIC...https://www.marketscreener.com/quote/stock/ORIC-PHARMACEUTICALS-INC-105997964/news/ORIC-Pharmaceuticals-Announces-125-Million-Private-Placement-Financing-45784774/?utm_medium=RSS&utm_content=20240122.
Verrica Pharmaceuticals Inc. (vrca) Q3 2023 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may begin your conference. Thank you, operator. Hello, everyone, and welcome to Verrica Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call.
Torrent Pharmaceutical In Talks With Apollo To Borrow Up To $1B For Cipla Bid
India's Torrent Pharmaceutical is in talks with Apollo Global Management for a loan of up to $1bn to fund a bid for Cipla.
Marinus Pharmaceuticals, Inc. (mrns) Q2 2023 Earnings Call Transcript
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Greetings and welcome to the Marinus Pharmaceuticals’ Second Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]. And now it is my pleasure to introduce you to your host, Sonya Weigle, Senior Vice President Investor Relations, Human Resources, and Corporate Affairs. You may now begin Ms. Weigle. Thank you and good morning.
Tagworks Pharmaceuticals Announces $65M In Series A Financing To Advance Click-to-release Therapeutics
Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures Unique Click-to-Release platform enables on-target activation of antibody-drug conjugates (ADCs) and immunomodulators, as well as...
Dechra Pharmaceuticals Agrees £4.5bn Takeover Deal With Swedish Private Equity Firm
The agreement comes after Dechra Pharmaceuticals issued a profit warning last month. :
The Northwich-based vet products group has been in talks since April over the deal which, if backed by shareholders, would be one of the biggest take-private moves in the UK so far this year. The company floated on the London Stock Exchange in 2000 with an equity capitalisation of £60m. It now has operations in 26 countries and almost 2,500 employees.
Ariceum Therapeutics Announces Extension Of Series A Financing To EUR 47.75m To Advance Its Next Generation Radiopharmaceutical Clinical Pipeline
New investors, Andera Partners and Earlybird Venture Capital, join existing investor, Pureos Bioventures raising an additional EUR 22.75 million Funds will be used to advance clinical pipeline and further build Ariceum Therapeutics Olivier Litzka from Andera Partners and Christoph Massner...
Marinus Pharmaceuticals, Inc. (mrns) Q4 2022 Earnings Call Transcript
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Greetings everyone and welcome to the Marinus Pharmaceuticals’ Fourth Quarter and Full-Year 2022 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] It is now my pleasure to introduce your host, Sasha Damouni Ellis, Vice President of Corporate Affairs and Investor Relations. Please go ahead. Thank you and good morning.
Private Equity Giant Kkr To Buy Japan's Bushu Pharmaceuticals - Cna
FILE PHOTO: Trading information for KKR & Co is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., August 23, 2018. REUTERS/Brendan McDermid :Private equity giant KKR & Co Inc said on Tuesday it will buy Japanese drug developer Bushu Pharmaceuticals from Hong Kong-based private equity firm BPEA EQT, but did not disclose financial details of the deal. A Bloomberg report from August stated a transaction may value Bushu Pharma at upwards of 100 billion yen ($749 million), citing people familiar with the matter.
Full-life Technologies Completes $37M (usd) Series A Financing To Accelerate Development Of Its Radiopharmaceutical Pipeline And Radiotechnology Production Platform
SHANGHAI and BRUSSELS, May 26, 2022 /PRNewswire/ -- Full-Life Technologies ("Full-Life") today announced it completed a $37 million (USD) Series A financing round to advance the development of its radiopharmaceutical oncology product pipeline and its radiotechnology production platform....